DTP-poliovirus vaccine - Mitsubishi Tanabe Pharma

Drug Profile

DTP-poliovirus vaccine - Mitsubishi Tanabe Pharma

Alternative Names: BK-4SP; Diphtheria-toxoid tetanus-toxoid pertussis-PT-FHA-inactivated poliovirus combined vaccine; Tetrabik

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Research Foundation for Microbial Diseases of Osaka University
  • Developer BIKEN; Mitsubishi Tanabe Pharma Corporation
  • Class Bacterial vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 26 Oct 2012 Launched for Diphtheria in Japan (SC)
  • 26 Oct 2012 Launched for Pertussis in Japan (SC)
  • 26 Oct 2012 Launched for Poliomyelitis in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top